TR201907568T4 - [5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu. - Google Patents
[5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu. Download PDFInfo
- Publication number
- TR201907568T4 TR201907568T4 TR2019/07568T TR201907568T TR201907568T4 TR 201907568 T4 TR201907568 T4 TR 201907568T4 TR 2019/07568 T TR2019/07568 T TR 2019/07568T TR 201907568 T TR201907568 T TR 201907568T TR 201907568 T4 TR201907568 T4 TR 201907568T4
- Authority
- TR
- Turkey
- Prior art keywords
- methylindol
- fluorobenzene
- pyridin
- sulfonyl
- fluoro
- Prior art date
Links
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 title abstract 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 title abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Buluş, diğer formlara göre daha yüksek çözünürlüğe sahip olan ve bu nedenle stabil farmasötik formülasyonların hazırlanmasına yönelik faydalı olan [5-floro-3-({2-[(4- florobenzen)sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asedik asidin bir polimorfik formu ile ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1407820.8A GB201407820D0 (en) | 2014-05-02 | 2014-05-02 | Polymorphic form |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201907568T4 true TR201907568T4 (tr) | 2019-06-21 |
Family
ID=50980534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/07568T TR201907568T4 (tr) | 2014-05-02 | 2015-05-01 | [5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu. |
Country Status (8)
Country | Link |
---|---|
US (1) | US9951042B2 (tr) |
EP (1) | EP3137453B8 (tr) |
JP (1) | JP2017514841A (tr) |
GB (1) | GB201407820D0 (tr) |
RU (1) | RU2702343C2 (tr) |
TR (1) | TR201907568T4 (tr) |
UA (1) | UA121476C2 (tr) |
WO (1) | WO2015166280A1 (tr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
CN108949699B (zh) * | 2018-08-03 | 2020-09-04 | 江南大学 | 一种分泌美洛昔康单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
DK151884C (da) | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
US4363912A (en) * | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
US4478842A (en) | 1981-11-19 | 1984-10-23 | Ciba-Geigy Corporation | N-Substituted-2-pyridylindoles |
GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
DE3514696A1 (de) | 1985-04-24 | 1986-11-06 | Bayer Ag, 5090 Leverkusen | N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung |
US5214059A (en) | 1989-07-03 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
GB9122590D0 (en) | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
WO1993023374A1 (en) | 1992-05-08 | 1993-11-25 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
US5641800A (en) | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
JP3144805B2 (ja) | 1996-06-05 | 2001-03-12 | 株式会社 ビー・エム・エル | ヒトTh2特異的タンパク質及びこれをコードする遺伝子(B19)並びにこれに関連する形質転換体、組換えベクター及びモノクローナル抗体 |
US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
EE200000573A (et) | 1998-03-31 | 2002-04-15 | The Institutes For Pharmaceutical Discovery, Llc | Asendatud indoolalkaanhapped |
HUP0101625A3 (en) | 1998-04-28 | 2002-12-28 | Elbion Ag | New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same |
EP0984012A3 (en) | 1998-08-31 | 2001-01-10 | Pfizer Products Inc. | Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties |
TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
WO2001014882A1 (fr) | 1999-08-23 | 2001-03-01 | Bml, Inc. | Identification des proprietes d'une substance pour les recepteurs de prostaglandine d |
AU2001232785A1 (en) | 2000-01-14 | 2001-07-24 | The Institutes For Pharmaceutical Discovery, Llc | Methods for lowering uric acid levels |
WO2001064205A2 (en) | 2000-03-02 | 2001-09-07 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
JP2001247570A (ja) | 2000-03-08 | 2001-09-11 | Japan Tobacco Inc | インドール酢酸化合物及びその製造方法 |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
US6797708B2 (en) | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
EP1505061A4 (en) | 2002-05-16 | 2007-08-22 | Shionogi & Co | CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
EP1569899B1 (en) | 2002-12-10 | 2006-06-28 | Wyeth | Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
KR20050111314A (ko) | 2002-12-20 | 2005-11-24 | 암젠 인코포레이션 | 천식 및 알레르기성 염증 조절제들 |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
JP2007508363A (ja) | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
RU2367659C2 (ru) | 2003-11-05 | 2009-09-20 | Ф.Хоффманн-Ля Рош Аг | Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar) |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
US20090170897A1 (en) | 2004-04-20 | 2009-07-02 | Pfizer, Inc. | Method of Treating Neuropathic Pain |
EP1745800A4 (en) | 2004-04-26 | 2009-11-18 | Ono Pharmaceutical Co | NEW BLT2-MEDIATED DISEASE AND BLT2 BINDING AND CONNECTION |
GB0412914D0 (en) | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
CA2581338A1 (en) | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
GB2422829A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
GB2422830A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
JP5072594B2 (ja) | 2005-07-22 | 2012-11-14 | 塩野義製薬株式会社 | Pgd2受容体アンタゴニスト活性を有するインドール誘導体 |
ES2443022T3 (es) | 2005-08-12 | 2014-02-17 | Merck Frosst Canada Inc. | Derivados de indol como antagonistas del receptor CRTH2 |
GB0518783D0 (en) | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
GB0614068D0 (en) | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
GB0614066D0 (en) | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
GB0722216D0 (en) | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
GB0722203D0 (en) | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
EP2229358B1 (en) | 2007-12-14 | 2011-03-23 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
DK2250161T3 (da) * | 2008-01-18 | 2014-01-27 | Atopix Therapeutics Ltd | Forbindelser med CRTH2-antagonistaktivitet |
US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
JP2011509985A (ja) | 2008-01-18 | 2011-03-31 | プルマジェン セラピューティクス (アズマ) リミテッド | Crth2受容体に対して活性なインドール |
WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
US20100022613A1 (en) | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
EP2300425A4 (en) | 2008-06-24 | 2012-03-21 | Panmira Pharmaceuticals Llc | PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS |
GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
BR112014014558A8 (pt) | 2011-12-16 | 2017-07-04 | Atopix Therapeutics Ltd | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica |
GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
GB201407813D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
-
2014
- 2014-05-02 GB GBGB1407820.8A patent/GB201407820D0/en not_active Ceased
-
2015
- 2015-05-01 JP JP2016565442A patent/JP2017514841A/ja active Pending
- 2015-05-01 TR TR2019/07568T patent/TR201907568T4/tr unknown
- 2015-05-01 EP EP15721032.9A patent/EP3137453B8/en active Active
- 2015-05-01 US US15/308,290 patent/US9951042B2/en active Active
- 2015-05-01 RU RU2016142519A patent/RU2702343C2/ru active
- 2015-05-01 UA UAA201612235A patent/UA121476C2/uk unknown
- 2015-05-01 WO PCT/GB2015/051296 patent/WO2015166280A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
UA121476C2 (uk) | 2020-06-10 |
EP3137453A1 (en) | 2017-03-08 |
US20170121306A1 (en) | 2017-05-04 |
JP2017514841A (ja) | 2017-06-08 |
RU2016142519A3 (tr) | 2018-11-02 |
EP3137453B8 (en) | 2019-05-15 |
GB201407820D0 (en) | 2014-06-18 |
RU2016142519A (ru) | 2018-06-05 |
RU2702343C2 (ru) | 2019-10-08 |
EP3137453B1 (en) | 2019-02-27 |
US9951042B2 (en) | 2018-04-24 |
WO2015166280A1 (en) | 2015-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119731T1 (el) | Διαδικασια για την παρασκευη παραγωγων χολικου οξεος | |
CL2017001675A1 (es) | Derivados de quinazolina utilizados para tratar el vih | |
CR20140464A (es) | Compuestos de heterociclilo | |
CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
EA201401292A2 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
CO7160104A2 (es) | Inhibidores de virus de hepatitis c | |
TR201906366T4 (tr) | Polisiklik-karbamoilpiridon bileşiklerinin sentezi. | |
GT201400144A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
CR20140435A (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
EA201692548A1 (ru) | Минеральные аминокислотные комплексы активных веществ | |
EA201591567A1 (ru) | Новые производные пиридина | |
EA201791896A1 (ru) | Дезацетокситубулизин н и его аналоги | |
AR095727A1 (es) | Preparación de intermediarios de pirimidina | |
EA201591451A1 (ru) | Модуляторы flap | |
EA201591976A1 (ru) | Производные пурина в качестве агонистов каннабиноидного рецептора cb2 | |
NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
EA201500821A1 (ru) | Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов | |
BR112016028022A2 (pt) | compostos de sulfonamida e seus usos como inibidores de stat5 | |
TR201907568T4 (tr) | [5-floro-3-({2-[(4-florobenzen) sülfonil]piridin-3-il}metil)-2-metilindol-1-il]-asetik asidin polimorfik formu. | |
BR112016021910A2 (pt) | Processo de preparação de 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h-imidazo[4,5-b]piridin-2-il)piridin-2-amina | |
UY34595A (es) | Composición farmacéutica de liberación prolongada de trimetazidina |